| __timestamp | Dynavax Technologies Corporation | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 14097000000 |
| Thursday, January 1, 2015 | 22180000 | 14809000000 |
| Friday, January 1, 2016 | 37257000 | 14837000000 |
| Sunday, January 1, 2017 | 27367000 | 14784000000 |
| Monday, January 1, 2018 | 64770000 | 14455000000 |
| Tuesday, January 1, 2019 | 74986000 | 14350000000 |
| Wednesday, January 1, 2020 | 79256000 | 11615000000 |
| Friday, January 1, 2021 | 100156000 | 12703000000 |
| Saturday, January 1, 2022 | 131408000 | 13677000000 |
| Sunday, January 1, 2023 | 152946000 | 14771000000 |
| Monday, January 1, 2024 | 14730000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Pfizer Inc. and Dynavax Technologies Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. While Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, Dynavax has seen a dramatic increase, growing by over 760% from 2014 to 2023. This surge reflects Dynavax's aggressive expansion and investment strategies, particularly in the wake of its innovative vaccine developments. In contrast, Pfizer's consistent expenditure underscores its established market presence and operational efficiency. As we delve into these financial narratives, it becomes evident that while Pfizer maintains its stronghold, Dynavax is rapidly emerging as a formidable contender in the pharmaceutical arena.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Pfizer Inc.
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Comparing Revenue Performance: Pfizer Inc. or Dynavax Technologies Corporation?
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Pfizer Inc. and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation